Development of a standardized definition for clinically significant bleeding in the ASPirin in Reducing Events in the Elderly (ASPREE) trial

Contemporary Clinical Trials Communications

Volumn 11, Issue , 2018, Pages 30-36

  Margolis, Karen L ^a   Mahady, Suzanne E ^b   Nelson, Mark R ^c   Ives, Diane G ^d   Satterfield, Suzanne ^e   Britt, Carlene ^b   Ekram, Saifuddin ^b   Lockery, Jessica ^b   Schwartz, Erin C ^a   Woods, Robyn L ^b   McNeil, John J ^b   Wood, Erica M ^b  

^a HEALTHPARTNERS INSTITUTE   (United States)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF TASMANIA   (Australia)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Aspirin; Bleeding; Hemorrhage; Methods; Primary prevention

Indexed keywords

ACETYLSALICYLIC ACID;

AGED; ANEMIA; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CLINICALLY SIGNIFICANT BLEEDING; COMMUNITY LIVING; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEATH; DOUBLE BLIND PROCEDURE; DRUG SAFETY; ELDERLY CARE; ELECTIVE SURGERY; EMERGENCY CARE; ERYTHROCYTE TRANSFUSION; FEMALE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; POSTOPERATIVE HEMORRHAGE; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL;

EID: 85047457915     PISSN: 24518654     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.conctc.2018.05.015     Document Type: Article

References (24)

1. Antithrombotic Trialists Collaboration, Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:7329 (2002), 71–86 https://www.ncbi.nlm.nih.gov/pubmed/11786451.
2. Berger, J.S., Brown, D.L., Becker, R.C., Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis. Am. J. Med. 121:1 (2008), 43–49, 10.1016/j.amjmed.2007.10.002.
3. Guirguis-Blake, J.M., Evans, C.V., Senger, C.A., O'Connor, E.A., Whitlock, E.P., Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services Task Force. Ann. Intern. Med. 164:12 (2016), 804–813, 10.7326/M15-2113.
4. Chubak, J., Whitlock, E.P., Williams, S.B., Kamineni, A., Burda, B.U., Buist, D.S., Anderson, M.L., Aspirin for the prevention of cancer incidence and mortality: systematic evidence reviews for the U.S. Preventive Services Task Force. Ann. Intern. Med. 164:12 (2016), 814–825, 10.7326/M15-2117.
5. Whitlock, E.P., Burda, B.U., Williams, S.B., Guirguis-Blake, J.M., Evans, C.V., Bleeding risks with aspirin use for primary prevention in adults: a systematic review for the U.S. Preventive Services Task Force. Ann. Intern. Med. 164:12 (2016), 826–835, 10.7326/M15-2112.
6. Antithrombotic Trialists Collaboration, Baigent, C., Blackwell, L., Collins, R., Emberson, J., Godwin, J., Peto, R., Buring, J., Hennekens, C., Kearney, P., Meade, T., Patrono, C., Roncaglioni, M.C., Zanchetti, A., Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373:9678 (2009), 1849–1860, 10.1016/S0140-6736(09) 60503–1.
7. De Berardis, G., Lucisano, G., D'Ettorre, A., Pellegrini, F., Lepore, V., Tognoni, G., Nicolucci, A., Association of aspirin use with major bleeding in patients with and without diabetes. JAMA 307:21 (2012), 2286–2294, 10.1001/jama.2012.5034.
8. Li, L., Geraghty, O.C., Mehta, Z., Rothwell, P.M., Oxford Vascular, S., Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. Lancet 390:10093 (2017), 490–499, 10.1016/S0140-6736(17) 30770–30775.
9. Aspree Investigator Group, Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial. Contemp. Clin. Trials 36:2 (2013), 555–564, 10.1016/j.cct.2013.09.014.
10. Mehran, R., Rao, S.V., Bhatt, D.L., Gibson, C.M., Caixeta, A., Eikelboom, J., Kaul, S., Wiviott, S.D., Menon, V., Nikolsky, E., Serebruany, V., Valgimigli, M., Vranckx, P., Taggart, D., Sabik, J.F., Cutlip, D.E., Krucoff, M.W., Ohman, E.M., Steg, P.G., White, H., Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 123:23 (2011), 2736–2747, 10.1161/CIRCULATIONAHA.110.009449.
11. McNeil, J.J., Woods, R.L., Nelson, M.R., Murray, A.M., Reid, C.M., Kirpach, B., Storey, E., Shah, R.C., Wolfe, R.S., Tonkin, A.M., Newman, A.B., Williamson, J.D., Lockery, J.E., Margolis, K.L., Ernst, M.E., Abhayaratna, W.P., Stocks, N., Fitzgerald, S.M., Trevaks, R.E., Orchard, S.G., Beilin, L.J., Donnan, G.A., Gibbs, P., Johnston, C.I., Grimm, R.H., Aspree Investigator Group. Baseline characteristics of participants in the ASPREE (ASPirin in reducing events in the elderly) study. J Gerontol A Biol Sci Med Sci, 2017, 10.1093/gerona/glw342.
12. Gibson, C.M., Mehran, R., Bode, C., Halperin, J., Verheugt, F.W., Wildgoose, P., Birmingham, M., Ianus, J., Burton, P., van Eickels, M., Korjian, S., Daaboul, Y., Lip, G.Y., Cohen, M., Husted, S., Peterson, E.D., Fox, K.A., Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N. Engl. J. Med. 375:25 (2016), 2423–2434, 10.1056/NEJMoa1611594.
13. Schulman, S., Kearon, C., Subcommittee on control of anticoagulation of the Scientific Standardization, committee of the International Society on Thrombosis Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3:4 (2005), 692–694, 10.1111/j.1538-7836.2005.01204.x.
14. Peto, R., Gray, R., Collins, R., Wheatley, K., Hennekens, C., Jamrozik, K., Warlow, C., Hafner, B., Thompson, E., Norton, S., et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 296:6618 (1988), 313–316 https://www.ncbi.nlm.nih.gov/pubmed/3125882.
15. Steering Committee of the Physicians' Health Study Research Group, Final report on the aspirin component of the ongoing Physicians' Health Study. N. Engl. J. Med. 321:3 (1989), 129–135, 10.1056/NEJM198907203210301.
16. ETDRS Investigators, Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. JAMA 268:10 (1992), 1292–1300 https://www.ncbi.nlm.nih.gov/pubmed/1507375.
17. Hansson, L., Zanchetti, A., Carruthers, S.G., Dahlof, B., Elmfeldt, D., Julius, S., Menard, J., Rahn, K.H., Wedel, H., Westerling, S., Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351:9118 (1998), 1755–1762 https://www.ncbi.nlm.nih.gov/pubmed/9635947.
18. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. Lancet 351:9098 (1998), 233–241 https://www.ncbi.nlm.nih.gov/pubmed/9457092.
19. De Gaetano, G., Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 357:9250 (2001), 89–95 https://www.ncbi.nlm.nih.gov/pubmed/11197445.
20. Ridker, P.M., Cook, N.R., Lee, I.M., Gordon, D., Gaziano, J.M., Manson, J.E., Hennekens, C.H., Buring, J.E., A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N. Engl. J. Med. 352:13 (2005), 1293–1304, 10.1056/NEJMoa050613.
21. Ogawa, H., Nakayama, M., Morimoto, T., Uemura, S., Kanauchi, M., Doi, N., Jinnouchi, H., Sugiyama, S., Saito, Y., Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes Trial, I., Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 300:18 (2008), 2134–2141, 10.1001/jama.2008.623.
22. Belch, J., MacCuish, A., Campbell, I., Cobbe, S., Taylor, R., Prescott, R., Lee, R., Bancroft, J., MacEwan, S., Shepherd, J., Macfarlane, P., Morris, A., Jung, R., Kelly, C., Connacher, A., Peden, N., Jamieson, A., Matthews, D., Leese, G., McKnight, J., O'Brien, I., Semple, C., Petrie, J., Gordon, D., Pringle, S., MacWalter, R., Prevention of Progression of Arterial, D., Diabetes Study, G., Diabetes Registry, G., Royal College of Physicians, E., The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ, 337, 2008, a1840, 10.1136/bmj.a1840.
23. Fowkes, F.G., Price, J.F., Stewart, M.C., Butcher, I., Leng, G.C., Pell, A.C., Sandercock, P.A., Fox, K.A., Lowe, G.D., Murray, G.D., Aspirin for Asymptomatic Atherosclerosis, T., Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 303:9 (2010), 841–848, 10.1001/jama.2010.221.
24. Ikeda, Y., Shimada, K., Teramoto, T., Uchiyama, S., Yamazaki, T., Oikawa, S., Sugawara, M., Ando, K., Murata, M., Yokoyama, K., Ishizuka, N., Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA 312:23 (2014), 2510–2520, 10.1001/jama.2014.15690.